A brief overview of the pathogenesis of scleroderma (systemic sclerosis)

E Carwile LeRoy

Although definitive answers are not yet forthcoming, understanding the mechanisms of fibrosis in scleroderma might improve the relative therapeutic vacuum now surrounding not only generalised scleroderma (systemic sclerosis (SSc)) but also the fibrosis of keloid formation, cirrhosis of the liver, pulmonary fibrosis, and atherosclerosis as well. Discussion here will include immune, vascular, and fibroblast/extracellular matrix features of SSc.

**Immune features**

Systemic sclerosis has been viewed as autoimmune since the introduction of indirect immunofluorescent antinuclear antibody determinations in the 1950s. Before the routine use (in the 1980s) of rapidly dividing, human cell substrates (HEp-2), SSc serum samples were only infrequently antinuclear antibody positive; since the introduction of HEp-2 cells more than 90% of serum samples from patients with SSc are antinuclear antibody positive. The table lists the various reactivities. Most of these are reported as either speckled or nucleolar pattern. The anticientomere antibody pattern is distinctive and, together with nailfold capillary examinations, has added considerably to the detection of the patient prone to connective tissue disease who presents with Raynaud’s phenomenon. Patients with anticientomere antibodies, with only rare exceptions, develop over the years limited cutaneous SSc. Most other antinuclear antibody specificities associated with SSc require subsidiary testing for precise assignment and, although some seem to be associated with selected HLA haplotypes, clinical and prognostic associations are not yet definite. Immunoblotting and enzyme linked immunosorbent assay (ELISA) techniques for antinuclear antibody determination are under study; unfortunately, these sensitive procedures may generate unnecessary (false positive) referrals.

**Autoimmune serology in systemic sclerosis (SSc)**

<table>
<thead>
<tr>
<th>Anticientomere antibodies</th>
<th>Antinuclear antibodies (speckled, nucleolar, other)</th>
<th>Antinuclear antibodies</th>
<th>RNA polymerase I</th>
<th>Fibrillarin (U3 RNA protein complex)</th>
<th>Nucleolar 4-65 RNA</th>
<th>U2 RNA protein complex</th>
<th>Polysyniotis/SSc overlap (PmSc)</th>
<th>Antitopoisoenase I (formerly ScI-70)</th>
<th>Anticollagen type I (interstitial collagen, ubiquitous)</th>
<th>Anticollagen type IV (basement membrane structure)</th>
<th>Antilaminin (basement membrane attachment protein)</th>
<th>Antiburconeldeprotein (RNP)</th>
<th>Jo-1</th>
<th>SS-A(Ro), SS-B(La)</th>
<th>Ku</th>
</tr>
</thead>
</table>

Emerging data from several laboratories indicate that a network of T lymphocytes is overactive in SSc. It is well known that most of the cutaneous cellular (perivascular and interstitial) infiltrates in SSc are T cells. Only recently has the T cell hyperactivity been localised to the T helper, CD4 positive, interleukin 2 dependent arm of the immune response. Circulating SSc T cells can be shown to be reactive to the basement membrane component laminin, to certain retroviral proteins, and, recently, to type I collagen; in addition, enhanced lymphocyte adhesion to endothelial cells can also be shown. This raises the intriguing possibility that T cells are auto-reactive to the endothelium (endothelial cell membrane, basal lamina matrix, others) throughout the vascular system. The precise autoepitopes of this reactivity can now be identified.

There are a variety of potential mechanisms by which T cells might become activated in SSc. They could be predisposed by the expression of a class II major histocompatibility complex gene on autologous antigen presenting cells to react strongly with any of the components listed as autoantigenic epitopes (table). These were epitopes integral structural components of the vasculature, a T cell directed attack on the vascular system could be self perpetuating. This hypothesis would predict that the T cell hyperactivity in SSc to vascular structures would be mediated through the antigen specific T cell receptor (CD3)—in effect, the classic autoimmune hypothesis.

There are other ways to activate T cells in SSc. The increased expression of extracellular matrix components by SSc fibroblasts, as well as the major alterations in the structure and function of the endothelium, creates tissue microenvironments likely to exhibit extracellular matrix epitopes which interact with T lymphocytes through a family of attachment proteins known as beta one (β1) integrins or VLA (very late antigen) T cell membrane molecules. Binding of integrins by the matrix stimulates T cells by mechanisms termed costimulation.

At least four matrix molecules may costimulate T cells already engaged by antigen specific mechanisms: (a) collagen (especially the basal lamina type IV molecule with many non-helical and therefore immunogenic epitopes); (b) fibronectin (especially "cellular" fibronectin expressing the type III connecting segment termed the CS-1 sequence); (c) laminin and its analogue merosin; and (d) the multimeric fibronectin-like molecule cytactin (tanascin).
A brief overview of the pathogenesis of scleroderma (systemic sclerosis)

Costimulation of T cells by matrix molecules is an intriguing phenomenon just beginning to be understood. In vitro engagement of the T cell receptor is a necessary but insufficient stimulus for T cell propagation; in fact, T cell receptor engagement in the absence of costimulatory signals makes the T cell tolerant rather than stimulating it; it is only in the presence of costimulatory signals that full T cell amplification occurs. In SSc, as in most other autoimmune disorders, the major T cell amplification is that of a subset consisting of CD4 positive, T helper, interleukin 2 dependent cells. Curiously, when the T cell receptor is engaged—for example, non-specifically by a monoclonal antibody (to CD3)—receptors for costimulation (VLA's) are not changed in number but are rendered more able (energised, activated) to induce mitogenesis, interleukin 2 secretion, and T cell amplification.15

Fibronectin, a multidomain attachment protein, binds to T cells through two receptors, VLA-4 and VLA-5; VLA-4 recognises in fibronectin a 10 amino acid sequence in the highly variable, alternatively spliced region of the molecule termed IIICS or CSI. This sequence, gyl - pro - glu - iso - leu - asp - val - pro - ser - thr (GPEILDPVST), with its rigid prolines and charged counterparts, might be expected to bind avidly (and additionally to be highly immunogenic). This domain is sparse in plasma but plentiful in 'cellular' fibronectin. Whereas T cells and natural killer cells bind fibronectin by both VLA-4 and VLA-5, B cells, capable of presenting antigen to T cells, bind fibronectin only through VLA-4. Returning to T cells, another site of fibronectin binding is between the classic arg-gly-asp (RGD) cell binding ligand and VLA-5. Such intricacy provides ample opportunity for cooperation between costimulatory receptors, and additive, synergistic, or other effects of signal transduction between these richly multiepitope ligands and such amply decorated T cell membranes. Little wonder that the quantitative effects of costimulation by matrix molecules are so impressive (in vitro).16

Laminin, the major constituent of the lamina rara of basal lamina of epithelia and endothelia, is a trimolecular complex resembling, when assembled, the Coptic Christian cross. Laminin, which in other cell types shows binding affinity for VLA-1, VLA-2, VLA-3, and VLA-6, binds T cells only through VLA-6. Full mapping of the epitope specificity of laminin—VLA-6 interaction on T cells awaits future study.17

Collagens were among the first extracellular molecules shown to bind several integrins (VLA-1, VLA-2, VLA-3) in a variety of cell types. There are now 14 known collagens, which have numerous structural variations. The epitopes of various collagens which bind integrins remain to be fully defined. In lymphocyte interactions the only binding convincingly shown is that of type I collagen to the VLA-3 integrin.11

Cytotactin (tenascin, a hexabrachion) is an extracellular matrix protein expressed in development and in tissue repair consisting of disulphide linked hexameric glycoprotein subunits which show homology to fibronectin. Cytotactin binds lymphocytes; the structural and functional implications of this binding are under active study.18

In SSc, in a study conducted before the full realisation of the potential for costimulatory effects, peripheral blood monocytes from patients with diffuse SSc were shown to initiate DNA synthesis on incubation with laminin. This was taken to represent cell mediated immunity to laminin in SSc without formal proof that the mitogenic signal was transmitted by the T cell receptor (CD3). On reconsideration, if SSc T cells were engaged with another non-laminin epitope by the T cell receptor, the data are consistent with a costimulatory role for laminin in SSc and do not necessarily indicate a direct immune response role. These earlier studies should now be re-examined in light of the potential role of T cell costimulatory effects.5

Clinically, immune activity relevant to fibrosis can be assessed by serial determinations of serum interleukin 2 concentrations, which have been shown to correlate positively with the progression of skin tautness in a group of 43 patients with diffuse SSc.19

Endothelial cell/vascular studies

Morphological evidence for vascular/microvascular involvement in SSc has accumulated for several decades, consisting of arterial intimal proliferation, capillary dilatation and destruction, and ultrastructural evidence for endothelial injury and detachment. The biological era of study began in 1979 with the observation that SSc serum samples (and plasma) contained an endothelial cytotoxic factor, protein in nature, about 50 kDa molecular mass, and associated with a functional decrease in serum serpin or proteinase inhibitor levels in the same serum samples.20 21 In 1990 the endothelial cytotoxic factor was tentatively identified as a serine proteinase present in the granules of activated T lymphocytes called granzyme A in the mouse and granzyme 1 in man.22 Free granzyme 1 has been identified in SSc serum samples by ELISA, and monoclonal antibody to granzyme 1 abrogates completely the endothelial cytotoxicity of SSc serum samples. Additional features of granzyme 1 are its ability to degrade collagen type IV and its inhibition by antithrombin III. What activates T cells in SSc and why they are unusually adherent to endothelium remains for further study. Clinically useful evidence of active endothelial injury can be obtained by determining plasma factor VIII-von Willebrand factor levels as an adjunct to management and treatment.23

Fibroblast/matrix studies

In 1972 mass cultures of fibroblasts from clinically and histologically affected skin of patients with SSc were shown to secrete increased amounts of collagen proteins, a phenotypic characteristic which persisted for several population doublings in vitro.24 In situ hybridisation has confirmed that mRNA for collagen α1 (I) can be detected in some but not all fibroblast-like cells in SSc skin biopsy specimens.25 Further in vitro studies have shown that colla-
gens I, III, and VI, fibronectin, and proteoglycan are all overexpressed at the transcriptional or message level. What types of cytokines are known to coordinate and upregulate these matrix molecules at the mRNA level? The leading candidate is transforming growth factor β, which, through receptors yet to be cloned and signal transduction mechanisms still poorly understood, increases mRNA levels of these and perhaps other matrix constituents. Whether this cytokine functions by increasing mRNA synthesis or decreasing mRNA decay, or both, is unclear. Direct evidence for transforming growth factor β involvement in SSc includes the in situ identification of the cytokine in the microenvironment of fibroblasts expressing collagen mRNA in SSc skin biopsy specimens. It is now appropriate to determine if common protein activators of gene expression are responsible for the several matrix genes overexpressed in SSc. If one or more transacting DNA binding regulators of gene expression can be identified it might become feasible to treat SSc with diffusible oligonucleotides which prevent the expression of these regulating proteins and thereby prevent fibrosis.

Systemic sclerosis fibroblasts also exhibit a cell growth abnormality not yet linked to matrix secretion. In contrast with healthy adult human skin fibroblasts, SSc fibroblasts are resistant to the induction of quiescence by serum deprivation, continuing to synthesize DNA and to express the immediate response proto-oncogene, c-myc. Systemic sclerosis fibroblasts also show heightened expression of platelet derived growth factor α (PDGF-α) receptors after eight hours' exposure to transforming growth factor β compared with healthy fibroblasts. We propose that the PDGF-α ligand/α receptor system affects wound healing and fibrosis. We are presently engaged in studying the regulation of expression of the α receptor, which is the only receptor through which PDGF-α induces signal transduction, whereas PDGF-β, the product of the c-sis gene, binds α and β receptors equally. Ultimately, we propose that control of SSc fibroblast cell proliferation may be possible through control of PDGF-α ligand/α receptor expression.

Summing up, unknown stimuli induce a T cell immune response with enhanced lymphocyte adherence to endothelium and release of granulocyte 1. These are both likely to contribute to the widespread vascular and microvascular injury that interferes with vascular permeability and exposes the interstitium to one or more fibrogenic cytokines which stimulate fibroblast proliferation and matrix gene expression resulting in fibrosis. Matrix expression continues to activate T cells and the cycle begins anew. Several potential sites at which this cycle can be interrupted represent potential therapeutic strategies for SSc.
A brief overview of the pathogenesis of scleroderma (systemic sclerosis).

E C LeRoy

doi: 10.1136/ard.51.2.286

Updated information and services can be found at:
http://ard.bmj.com/content/51/2/286.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/